Related Experiment Video
Updated: Oct 26, 2025
Tilt Testing with Combined Lower Body Negative Pressure: a "Gold Standard" for Measuring Orthostatic Tolerance
Published on: March 21, 2013
Midodrine for the Prevention of Vasovagal Syncope : A Randomized Clinical Trial
Robert Sheldon1, Peter Faris1, Anthony Tang2
1University of Calgary, Calgary, Alberta, Canada (R.S., P.F., C.A.M., D.R., S.S., C.M.).
Background:
Recurrent vasovagal syncope is common, responds poorly to treatment, and causes physical trauma and poor quality of life. Midodrine prevents hypotension and syncope during tilt tests in patients with vasovagal syncope.
Objective:
To determine whether midodrine can prevent vasovagal syncope in usual clinical conditions.
Design:
Randomized, double-blind, placebo-controlled clinical trial. (ClinicalTrials.gov: NCT01456481).
Setting:
25 university hospitals in Canada, the United States, Mexico, and the United Kingdom.
Patients:
Patients with recurrent vasovagal syncope and no serious comorbid conditions.
Intervention:
Patients were randomly assigned 1:1 to placebo or midodrine and followed for 12 months.
Measurements:
The primary outcome measure was the proportion of patients with at least 1 syncope episode during follow-up.
Results:
The study included 133 patients who had had a median of 6 syncope episodes in the prior year (median age, 32 years; 73% female). Compared with patients receiving placebo, fewer patients receiving midodrine had at least 1 syncope episode (28 of 66 [42%] vs. 41 of 67 [61%]). The relative risk was 0.69 (95% CI, 0.49 to 0.97; P = 0.035). The absolute risk reduction was 19 percentage points (CI, 2 to 36 percentage points), and the number needed to treat to prevent 1 patient from having syncope was 5.3 (CI, 2.8 to 47.6). The time to first syncope was longer with midodrine (hazard ratio, 0.59 [CI, 0.37 to 0.96]; P = 0.035; log-rank P = 0.031). Adverse effects were similar in both groups.
Limitation:
Small study size, young and healthy patients, relatively short observation period, and high proportion of patients from 1 center.
Conclusion:
Midodrine can reduce the recurrence of syncope in healthy, younger patients with a high syncope burden.
Primary Funding Source:
The Canadian Institutes of Health Research.
More Related Videos
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
05:58Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
Related Concept Videos
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
01:28Drugs Acting on Autonomic Ganglia: Blockers
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
01:28Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...